If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
80.90    -3.80 (-4.49%)
Bid:
81.50
Ask:
82.30
Spread: 0.80 (0.982%)
Market Cap: £132.63m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q1 Trading and COVID-19 Update

29 Apr 2020 07:00

RNS Number : 2338L
Synthomer PLC
29 April 2020
 

29th April 2020

 

Synthomer plc

Q1 Trading and COVID-19 Update

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended 31st March 2020.

Q1 Trading

As announced previously, the Group has experienced a solid start to the year with EBITDA approximately 5% ahead of the comparative Q1 period for the heritage business, and in line with expectations set out at the time of Synthomer's full year results announcement.

Performance Elastomers

Our Nitrile Butadiene Latex ('Nitrile') business continued to benefit from the additional 90kt of capacity introduced in Q4 2018 at our Pasir Gudang site. We saw higher volumes due to COVID-19, although unit margins were marginally lower relative to a strong comparative period in 2019. Styrene Butadiene Rubber ('SBR') market conditions stabilised with volumes in line and unit margins ahead of prior year. The strategic review of our European SBR network is ongoing and a further update will be provided in due course.

Functional Solutions

Whilst reported volumes were lower than the comparative period this was compensated for by stronger unit margins as a result of improved mix and softer raw material markets. Progress has been supported by the expansion of our Worms, Germany and Roebuck, USA dispersions facilities last year which introduced low cost capacity to drive organic growth in differentiated applications.

Industrial Specialities

Performance has continued in line with expectations. Excluding the impact of our acrylate monomer business, which largely supplies internal demand, all businesses made progress with volumes in line and margins ahead of the comparative period in 2019.

COVID-19 Update

The Group continues to operate 37 of its 38 global manufacturing sites, with speciality chemicals designated as key industrial assets in the geographies in which Synthomer operates. To date, the Group has experienced no significant issues with regards to raw material supply, the distribution of finished goods or the availability of operating personnel.

Notwithstanding Synthomer's broad geographic and end market diversity, Q2 sales into industrial markets including Automotive and the Oil & Gas sector are currently being impacted. However demand for Nitrile continues to be strong particularly as a result of the COVID-19 pandemic.

 

As previously announced, the Group has a strong balance sheet with significant leverage covenant headroom (4.25x and 4.00x EBITDA for 2020 and 2021), and significant liquidity underpinned by the 2024 committed unsecured 5 year €460m RCF and $260m term loan bank facilities.  

 

Synthomer expects to reduce its capital expenditure for 2020 to approximately £50m from the £73.5m originally anticipated (including OMNOVA). The Group has recently completed a material capital expenditure programme and its asset base remains well invested.

Under the current circumstances, the Group's Board, Executive and Senior Management have frozen their salaries at 2019 levels and delayed any further review until October 2020.

Following the completion of the OMNOVA transaction, as announced on the 1st April 2020, the ongoing integration of the business is progressing. We confirm delivery of the expected $29.6m synergy is on track. OMNOVA reported EBITDA Q1 2020 marginally ahead of Q1 2019 but given their exposure to a broad range of industrial markets expect an impact from the COVID-19 pandemic in the months ahead.

Outlook

Given the unprecedented uncertainty around the impact of COVID-19, it is unclear what impact this will have on the Group's financial performance for the year. As such, the Group is withdrawing its previous guidance for the year ending 31st December 2020 and will update the market when there is better visibility.

Over the medium term the Board remains confident that Synthomer is well positioned due to the Group's strong geographic and end market diversity combined with self-help initiatives and the future benefits to come from the successful acquisition and integration of OMNOVA.

-ENDS-

 

Enquiries:

 

Synthomer plc

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, President, Corporate Development

Tel: + 44 7764 859147

 

 

Teneo

Charles Armitstead / Matt Denham

Tel: + 44 7703 330 269

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSEUFAAESSEEL
Date   Source Headline
26th Jun 20263:53 pmRNSDirector/PDMR Shareholding
22nd Jun 20261:31 pmRNSResults of AGM
22nd Jun 20267:00 amRNSAGM trading statement
19th Jun 20267:00 amRNSDivestment of Acrylate Monomers
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.